BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4446
- TODAY'S CHANGE (%)-0.0068 (-1.5064%)
- Bid / Lots0.4002/ 10
- Ask / Lots0.4600/ 20
- Open / Previous Close0.4500 / 0.4514
- Day Range
- 52 Week Range
- Volume225,865
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 6833 | 0.4549 |
| 09:42 ET | 5697 | 0.45 |
| 09:51 ET | 2000 | 0.442501 |
| 09:57 ET | 100 | 0.44 |
| 10:04 ET | 844 | 0.44 |
| 10:06 ET | 500 | 0.4475 |
| 10:08 ET | 10100 | 0.445 |
| 10:11 ET | 168 | 0.445 |
| 10:13 ET | 284 | 0.4492 |
| 10:15 ET | 20100 | 0.4499 |
| 10:20 ET | 6648 | 0.445 |
| 10:22 ET | 600 | 0.4488 |
| 10:33 ET | 400 | 0.4466 |
| 10:36 ET | 100 | 0.4477 |
| 10:42 ET | 100 | 0.4487 |
| 10:49 ET | 690 | 0.4487 |
| 10:51 ET | 400 | 0.4487 |
| 10:56 ET | 4200 | 0.442 |
| 11:00 ET | 100 | 0.4436 |
| 11:03 ET | 5100 | 0.4456 |
| 11:07 ET | 200 | 0.442 |
| 11:16 ET | 4300 | 0.4496 |
| 11:18 ET | 4000 | 0.4496 |
| 11:27 ET | 300 | 0.4495 |
| 11:36 ET | 2500 | 0.445451 |
| 11:39 ET | 140 | 0.445449 |
| 11:41 ET | 250 | 0.4493 |
| 11:43 ET | 100 | 0.449299 |
| 11:59 ET | 1000 | 0.449 |
| 12:03 ET | 130 | 0.44151 |
| 12:15 ET | 200 | 0.4453 |
| 12:28 ET | 250 | 0.4464 |
| 12:37 ET | 100 | 0.4463 |
| 12:46 ET | 5014 | 0.44545 |
| 12:48 ET | 500 | 0.4445 |
| 01:04 ET | 300 | 0.4498 |
| 01:20 ET | 1500 | 0.4474 |
| 01:33 ET | 600 | 0.4462 |
| 01:44 ET | 1000 | 0.446845 |
| 01:51 ET | 108 | 0.4472 |
| 01:56 ET | 200 | 0.4473 |
| 02:05 ET | 100 | 0.4496 |
| 02:07 ET | 400 | 0.4498 |
| 02:09 ET | 8058 | 0.4499 |
| 02:12 ET | 100 | 0.44985 |
| 02:25 ET | 300 | 0.4499 |
| 02:39 ET | 10100 | 0.446 |
| 02:41 ET | 300 | 0.4497 |
| 02:45 ET | 300 | 0.4475 |
| 02:52 ET | 248 | 0.4466 |
| 02:54 ET | 100 | 0.4475 |
| 03:01 ET | 2600 | 0.44745 |
| 03:06 ET | 10300 | 0.44745 |
| 03:14 ET | 300 | 0.4475 |
| 03:17 ET | 950 | 0.4479 |
| 03:21 ET | 9600 | 0.4469 |
| 03:26 ET | 15100 | 0.4465 |
| 03:30 ET | 400 | 0.4469 |
| 03:32 ET | 54499 | 0.44 |
| 03:35 ET | 1100 | 0.4435 |
| 03:37 ET | 2100 | 0.447 |
| 03:46 ET | 2100 | 0.4457 |
| 03:48 ET | 100 | 0.4457 |
| 03:50 ET | 2260 | 0.443099 |
| 03:51 ET | 100 | 0.446 |
| 03:55 ET | 5000 | 0.4488 |
| 03:57 ET | 1000 | 0.445 |
| 04:00 ET | 600 | 0.4446 |
Nov 6, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 7:55AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:55AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Oct 16, 2024
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 39.6M | -0.6x | --- |
Marker Therapeutics Inc | 36.9M | -3.6x | --- |
Palatin Technologies Inc | 25.4M | -0.7x | --- |
Dyadic International Inc | 33.6M | -4.3x | --- |
Lumos Pharma Inc | 37.7M | -1.0x | --- |
Kronos Bio Inc | 49.7M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $39.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.49 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 3.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
